It was announced at the end of last week that JHL and Genentech had reached a settlement agreement whereby the former company forfeited its development of biosimilars related to the case.
Genentech had accused JHL of conspiring with its former employees in the development of biosimilars to Rituxan (rituximab), Pulmozyme (dornase alfa), Herceptin (trastuzumab), and Avastin (bevacizumab).
With the announcement of a settlement agreement, JHL confirmed that it would resolve Genentech’s civil claims by ceasing the development and clinical trials of biosimilar rivals to these products.
In addition, JHL will reimburse Genentech’s legal fees and the cost of its internal investigation but noted that it would not pay any damages.
Cody Harris, a partner at Keker, Van Nest & Peters, which represented Genentech in the case, added, “Unlike the usual settlement, which brings work to a close, this one kicks off an extremely active phase in the case, in which we will thoroughly investigate JHL’s misconduct, ensure compliance with the settlement, and continue pursuing Genentech’s claims against the remaining individual defendants.”
Read the full report here.